Ensayos clínicos

8.676 ensayos encontrados

ReclutandoFase 3ClinicalTrials.gov

A Phase 3, Open Label, Multicenter, Randomized Study of First Line Tarlatamab in Combination With Durvalumab, Carboplatin and Etoposide Versus Durvalumab, Carboplatin and Etoposide in Untreated Extensive Stage Small-Cell Lung Cancer (DeLLphi-312)

INTERVENTIONALInicio: 18 de ago de 2025ID: NCT07005128

CompletadoFase 4ClinicalTrials.gov

A Randomized, Double-blind, Placebo-controlled Two-year Trial to Examine the Changes in Exercise Endurance and COPD Treated With Tiotropium Once Daily (EXACTT)

INTERVENTIONALInicio: 1 de ago de 2007ID: NCT00525512

ReclutandoFase 2ClinicalTrials.gov

A Phase 2, Multicenter, Randomized, Double-blind, 52-week Study, to Investigate the Efficacy and Safety of Brenipatide Compared With Placebo for the Treatment of Adult Participants With Uncontrolled Moderate to Severe Asthma

INTERVENTIONALInicio: 22 de oct de 2025ID: NCT07219173

ReclutandoFase 3ClinicalTrials.gov

A Randomized, Open-label, Phase 3 Study of MK-2870 vs. Platinum Doublets in Participants With EGFR-mutated, Advanced Nonsquamous Non-small Cell Lung Cancer (NSCLC) Who Have Progressed on Prior EGFR Tyrosine Kinase Inhibitors

INTERVENTIONALInicio: 11 de jun de 2024ID: NCT06305754

CompletadoFase 3ClinicalTrials.gov

A Stratified, Randomized, Double-blind, Placebo-controlled, Parallel-group, 12 Week Trial Evaluating the Safety and Efficacy of Fluticasone Propionate/Salmeterol DISKUS Combination Product 100/50mcg Once Daily Versus Fluticasone Propionate DISKUS 100mcg Once Daily and Placebo in Symptomatic Pediatric Subjects (4-11 Years) With Asthma

INTERVENTIONALInicio: 1 de nov de 2001ID: NCT00920959

DesconocidoClinicalTrials.gov

Respiratory System Mechanics and Gas Exchange Characteristics Applying Different Ventilatory Strategies in Patients With SARS-CoV-2

OBSERVATIONALInicio: 1 de jul de 2020ID: NCT04486729

Activo, no reclutaClinicalTrials.gov

Proportional Assist Ventilation Plus and Estimation of Respiratory Effort in Critically Ill Patients During the Transition to Spontaneous Ventilation: A Prospective Cohort Study

OBSERVATIONALInicio: 1 de feb de 2024ID: NCT06998927

TerminadoFase 3ClinicalTrials.gov

Reparixin 1200 mg TID as add-on to SoC to Limit Disease Progression in Hospitalised Patients With COVID-19 and Other Community-Acquired Pneumonia. A Multicentre, Randomized, Double-blinded, Placebo-controlled, Phase III Trial (REPAVID-22)

INTERVENTIONALInicio: 27 de abr de 2022ID: NCT05254990

TerminadoFase 2ClinicalTrials.gov

A Phase 2b, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Antiviral Activity, Clinical Outcomes, Safety, Tolerability, and Pharmacokinetics of Orally Administered Lumicitabine Regimens in Adult Subjects Hospitalized With Respiratory Syncytial Virus

INTERVENTIONALInicio: 25 de oct de 2016ID: NCT02935673

CompletadoFase 3ClinicalTrials.gov

Randomized, Double-blind, Placebo-controlled, Multi-centre, Multi-national Study to Evaluate the Efficacy and Safety of Oral BAY63-2521 (1 mg, 1.5 mg, 2 mg, or 2.5 mg Tid) in Patients With Symptomatic Pulmonary Arterial Hypertension (PAH)

INTERVENTIONALInicio: 17 de dic de 2008ID: NCT00810693

CompletadoFase 4ClinicalTrials.gov

A Phase III/IV, Single Arm, Multicenter Study of Atezolizumab (Tecentriq) to Investigate Long-term Safety and Efficacy in Previously-treated Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer (TAIL)

INTERVENTIONALInicio: 25 de oct de 2017ID: NCT03285763

ReclutandoFase 3ClinicalTrials.gov

A Phase 3, Randomized, Open-label Study of Nivolumab + Relatlimab Fixed-dose Combination With Chemotherapy Versus Pembrolizumab With Chemotherapy as First-line Treatment for Participants With Non-squamous (NSQ), Stage IV or Recurrent Non-small Cell Lung Cancer and With Tumor Cell PD-L1 Expression ≥ 1%

INTERVENTIONALInicio: 7 de oct de 2024ID: NCT06561386

Activo, no reclutaFase 3ClinicalTrials.gov

A Phase 3, Prospective, Multicenter, Double-blind, Double-dummy, Randomized, Active-controlled, Parallel-group, Group-sequential, Adaptive, Event-driven Study to Compare Efficacy, Safety, and Tolerability of Macitentan 75 mg Versus Macitentan 10 mg in Patients With Pulmonary Arterial Hypertension, Followed by an Open-label Treatment Period With Macitentan 75 mg

INTERVENTIONALInicio: 30 de jun de 2020ID: NCT04273945

CompletadoFase 4ClinicalTrials.gov

Study to Evaluate the Effect of Roflumilast 500 μg on Exacerbation Rate in Subjects With Chronic Obstructive Pulmonary Disease (COPD) Treated With a Fixed-Dose Combination of Long-Acting Beta Agonist and Inhaled Corticosteroid (LABA/ICS)

INTERVENTIONALInicio: 30 de sept de 2011ID: NCT01443845

CompletadoFase 2ClinicalTrials.gov

A Phase 2b, Randomized Study to Evaluate the Efficacy and Safety of Subcutaneous MEDI-528 in Adults With Uncontrolled Asthma

INTERVENTIONALInicio: 1 de dic de 2009ID: NCT00968669

CompletadoFase 3ClinicalTrials.gov

A Phase III, Randomized, Double-Blinded, Multi-Center, Study to Assess the Efficacy of Docetaxel (TAXOTERE™) in Combination With ZD6474 (ZACTIMA™) Versus Docetaxel (TAXOTERE™) With Placebo in Subjects With Locally Advanced or Metastatic NSCLC

INTERVENTIONALInicio: 1 de may de 2006ID: NCT00312377

CompletadoClinicalTrials.gov

Prospective Epidemiological Study of Metastatic Non Small Cell Lung Cancer (NSCLC) in Latin America

OBSERVATIONALInicio: 25 de jul de 2018ID: NCT04227457

ReclutandoFase 3ClinicalTrials.gov

A Double Blind, Randomized, Placebo-controlled Exploratory Trial to Investigate the Efficacy and Safety of Nerandomilast Over 24 Months When Administered in Individuals With Interstitial Lung Abnormalities and a Family History of Pulmonary Fibrosis to Reduce the Risk of Worsening (DROP-FPF)

INTERVENTIONALInicio: 10 de feb de 2026ID: NCT07201922

TerminadoFase 3ClinicalTrials.gov

A Double-blind, Randomized, Placebo-controlled Study to Assess the Safety and Efficacy of Nebulized PC945 When Added to Systemic Antifungal Therapy for the Treatment of Refractory Invasive Pulmonary Aspergillosis (OPERA-T Study)

INTERVENTIONALInicio: 14 de jun de 2022ID: NCT05238116

Activo, no reclutaFase 3ClinicalTrials.gov

A Phase 3, 52-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel-Arm Efficacy and Safety Study With Open-Label Extension of BLU-5937 in Adult Participants With Refractory Chronic Cough, Including Unexplained Chronic Cough (CALM-1)

INTERVENTIONALInicio: 25 de oct de 2022ID: NCT05599191